Member Info for Larus

OPTI now at the same price it was when its SBTX statke was 32p. Which is now 49p, valuing the entire OPTI business at just £17.5m. Quite mad really. And a bargain.

A few people really ruined their pants this morning on Ukraine news. Opportunity knocks when they've wiped themselves off.

This was announced on Nov 1st last year (see RNS)

https://www.youtube.com/watch?v=Mn1URa91lj0

Agree, Stephen needs to get away from subscription only interviews and stick to the professional platforms with a wider reach.

Speaking of which...

Someone on this board recently confidently asserted (contrary to company communication) that LPLDL wasn't a replacement for statins.

The recent tweet by Cholbiome would confirms this was incorrect https://twitter.com/CholBiome/status/1492103653007802369

Lol every now and then draft pops up to tell us how awful it is that the price has dropped and how difficult it will be to go back up again. Or maybe just to tell us how terrible it is that some warrants have been issued

The interview was advertised beforehand by Opti, it was pre-arranged

...and now the Norland disposal RNS from 31st.

Here is a link to one of Dr Ranj's appearances yesterday. https://open.spotify.com/episode/72wv2uqv9bhaYnku58KReh

Notice that another of OPTI's partners was high in the degestive list with VSL3

SOH plays with a pretty straight bat. He doesn't chat sh*t to people like Winnifroth

Lol someone missed the bottom

Skid, we need to stick to the facts indeed. LPLDL is not a new product, and it is not a drug (it is a food supplement), so it would not be subject to a multi phase clinical trial as you suggest. It has already passed all the requisite safetly, tolerability and efficacy trials that would be typical of a phase 1 and 2 study some years ago. So yes, these results can be regarded as a proper clinical trial. The company has also indicated from previous releases that it is also exploring moving LPLDL along the pharmaceutical route in addition to over the counter.

basscadet, the study was a nine-week follow-up, single centre, double-blind, randomised, placebo controlled human intervention study. Not sure what you're expecting a proper medical trial to look like

The presentation is here: https://www.youtube.com/watch?v=j5WW9Geo0rg&t=1863s

18.60 equivalent buys on ASX last night, yours for 16.75 this morning. Somehow the dip in U3O8 equities overnight shaken off in this share

https://www.thisismoney.co.uk/money/investing/article-10390169/SMALL-CAP-IDEAS-Biotech-firm-Optibiotix-set-build-momentum.html

Skid, I'm afraid it's all laid out in the RNS. It really is simple enough for anyone with a basic knowledge of share options to understand.

Belgrano have you read all of the RNS? Options can only be exercised when certain performance criteria are met. Which at present, they haven't. So there won't be any exercised or sold until those milestones are reached